Physician profile
Robert D Haydel
NPI 1891791240
$1,978.82
in general payments reported to CMS, 2019-2025
9 companies · $337 in 2025
The $337 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $123 · 2021: $207 · 2022: $382 · 2023: $375 · 2024: $279 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.63 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,344.10 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $192.76 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.00 | 2025 | Takhzyro |
| Regeneron Healthcare Solutions, INC. | $94.18 | 2024 | Dupixent |
| Genentech USA, INC. | $81.36 | 2019-2020 | |
| Amgen INC. | $48.51 | 2023-2025 | Tezspire |
| Sunovion Pharmaceuticals INC. | $47.74 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $45.61 | 2020 | |
| Azurity Pharmaceuticals, INC. | $25.56 | 2025 | Alvesco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Haydel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.